Article Figures & Data
Figures
- FIGURE 1.
Cell-associated radioactivity as function of time after interrupted incubation of SKOV-3 cells with 188Re-ZHER2:V2. Data are presented as average value from 3 cell dishes ± SD. Error bars might not be seen because they are smaller than point symbols.
- FIGURE 2.
In vivo binding specificity of 188Re-ZHER2:V2 in mice bearing ovarian cancer SKOV-3 xenografts at 4 h after injection. Blocked group was subcutaneously preinjected with excess amount of nonlabeled ZHER2:342. Results are presented as %IA/g.
- FIGURE 3.
Imaging of HER2 expression in SKOV-3 ovarian cancer xenografts (high HER2 expression) in NMRI nu/nu mice using 188Re-ZHER2:V2. Planar scintillation-camera images were acquired at 1 h (A) and 4 h (B) after injection. Arrows point to tumors (T) and kidneys (K).
- FIGURE 4.
Tumor-absorbed dose vs. mass for 188Re-ZHER2:V2.
Tables
- TABLE 1
Biodistribution of 188Re-ZHER2:V2 in NMRI nu/nu Mice Bearing HER2-Expressing SKOV-3 Xenografts
Uptake Organ 20 min 1 h 4 h 8 h 24 h 48 h Blood 3.0 ± 0.3 1.4 ± 0.1 0.3 ± 0.1 0.05 ± 0.02 0.02 ± 0.01 0.006 ± 0.003 Heart 1.4 ± 0.3 0.6 ± 0.1 0.11 ± 0.02 0.05 ± 0.01 0.02 ± 0.01 NM Lung 3.4 ± 0.2 1.7 ± 0.2 0.28 ± 0.05 0.08 ± 0.03 0.03 ± 0.01 NM Salivary gland 1.6 ± 0.5 1.1 ± 0.3 0.2 ± 0.1 0.06 ± 0.03 0.02 ± 0.01 NM Thyroid* 0.07 ± 0.02 0.04 ± 0.02 0.01 ± 0.001 0.01 ± 0.004 0.002 ± 0.001 NM Liver 3.4 ± 0.3 2.2 ± 0.2 0.51 ± 0.09 0.26 ± 0.06 0.12 ± 0.03 0.06 ± 0.016 Spleen 1.5 ± 0.2 0.87 ± 0.06 0.16 ± 0.02 0.08 ± 0.01 0.03 ± 0.01 NM Pancreas 0.8 ± 0.2 0.4 ± 0.1 0.08 ± 0.03 0.030 ± 0.003 0.01 ± 0.01 NM Stomach 2.0 ± 0.08 1.3 ± 0.23 0.3 ± 0.1 0.08 ± 0.01 0.08 ± 0.07 NM Small intestine 1.4 ± 0.1 0.9 ± 0.2 0.16 ± 0.08 0.08 ± 0.07 0.04 ± 0.03 NM Large intestine 1.9 ± 0.08 1.2 ± 0.6 0.19 ± 0.05 0.3 ± 0.3 0.04 ± 0.01 0.02 ± 0.004 Kidney 47 ± 2 18 ± 3 2.1 ± 0.2 1.0 ± 0.2 0.51 ± 0.08 0.30 ± 0.12 Tumor 8.7 ± 0.9 14 ± 2 12 ± 2 8.0 ± 0.6 5 ± 2 1.8 ± 0.5 Skin 2.4 ± 0.4 1.4 ± 0.1 0.6 ± 0.5 0.10 ± 0.02 0.04 ± 0.02 0.02 ± 0.005 Muscle 0.6 ± 0.1 0.28 ± 0.03 0.06 ± 0.03 0.02 ± 0.01 0.02 ± 0.01 NM Bone 1.0 ± 0.1 0.6 ± 0.1 0.12 ± 0.01 0.05 ± 0.02 0.04 ± 0.02 NM Brain 0.08 ± 0.02 0.05 ± 0.01 0.020 ± 0.003 0.01 ± 0.001 0.01 ± 0.002 NM Carcass* 23 ± 2 14 ± 4 2 ± 1 1.1 ± 0.9 0.35 ± 0.09 0.19 ± 0.04 ↵* Data for thyroid and carcass are presented as %IA per whole sample.
NM = not measurable, below detection limit.
Uptake is expressed as %IA/g and presented as average value from 4 animals ± SD. Data are corrected for decay and self-attenuation in samples.
- TABLE 2
Calculated Absorbed Dose (Gy/MBq) for 188Re-ZHER2:V2 in Mice Using Murine Moby Phantom
Organ Self-dose Total absorbed dose Blood 0.008 0.099 Heart 0.003 0.094 Lung 0.019 0.14 Salivary gland 0.0062 0.11 Thyroid 0.00022 0.13 Liver 0.027 0.079 Spleen 0.0068 0.072 Pancreas 0.0024 0.075 Stomach 0.014 0.061 Small intestine 0.0058 0.076 Large intestine 0.0051 0.11 Kidney 0.17 0.23 Skin 0.0038 0.081 Bone 0.0019 0.10 Brain 0.00073 0.026 Carcass 0.16 0.16 Tumor 1 0.40 0.43 Tumor 2 0.40 0.43 Tumor 3 0.40 0.44 Bone marrow 0.0029 0.096 Tumors 1, 2, and 3 stand for tumors in right hind leg, left hind leg, and left flank, respectively.
- TABLE 3
Calculated Absorbed Dose (mGy/MBq) for 188Re-ZHER2:V2 in Humans Using OLINDA/EXM 1.0
Organ Absorbed dose, 188Re-ZHER2:V2 Adrenals 0.007 Brain 0.002 Breasts 0.006 Gallbladder wall 0.007 Lower large intestine wall 0.022 (0.046*) Small intestine 0.018 (0.014*) Stomach wall 0.007 Upper large intestine wall 0.034 Heart wall 0.006 Kidneys 0.189 Liver 0.029 Lungs 0.011 Muscle 0.006 Ovaries 0.007 Pancreas 0.006 Red marrow 0.010 Osteogenic cells 0.020 Skin 0.006 Spleen 0.009 Thymus 0.006 Thyroid 0.001 Urinary bladder wall 0.006 Uterus 0.007 Total body 0.009 Tumor 0.65 ↵* Using gastrointestinal tract model assuming 0.35% of injected dose entering small intestine.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
- Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting